checkAd
    Startseite > Aktien > Applied Therapeutics > Nachrichten
    Applied Therapeutics Aktie
    4,0860
     
    EUR
    -6,20 %
    -0,2700 EUR
    Letzter Kurs 10.05.24 Tradegate
    4,0140
     
    EUR
    1.498 STK
    Geldkurs 13:48:19
    4,1340
     
    EUR
    1.454 STK
    Briefkurs 13:48:19
    ISIN: US03828A1016 · WKN: A2PHHB · SYM: 2UV · USA

    Neueste Nachrichten

    Applied Therapeutics Reports First Quarter 2024 Financial Results
    09.05.24 · globenewswire · Applied Therapeutics
    Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
    07.05.24 · globenewswire · Applied Therapeutics
    Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
    15.04.24 · globenewswire · Applied Therapeutics
    Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
    04.04.24 · globenewswire · Applied Therapeutics
    Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
    28.03.24 · globenewswire · Applied Therapeutics
    Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
    06.03.24 · globenewswire · Applied Therapeutics
    Applied Therapeutics Announces $100 Million Private Placement
    28.02.24 · globenewswire · Applied Therapeutics
    Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
    28.02.24 · globenewswire · Applied Therapeutics
    Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency
    15.02.24 · globenewswire · Applied Therapeutics
    Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy
    04.01.24 · globenewswire · Applied Therapeutics
    Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia
    03.01.24 · globenewswire · Applied Therapeutics
    Applied Therapeutics Reports Third Quarter 2023 Financial Results
    09.11.23 · globenewswire · Applied Therapeutics